Lipid Efficacy/Tolerability Study (0524A-020)

Clinical Trial ID NCT00269204

Rank	Title	Journal	Year	PubWeight™‹?›
1	A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.	Gastroenterology	2006	3.35
2	Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.	Int J Clin Pract	2008	1.27
3	Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.	Clin Ther	2009	1.09
4	Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.	Clin J Am Soc Nephrol	2010	0.95
5	Effect of niacin on FGF23 concentration in chronic kidney disease.	Am J Nephrol	2014	0.85
6	Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.	Am J Cardiovasc Drugs	2012	0.82
7	Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.	Int J Clin Pract	2011	0.76